ES2496771T3 - Polvo de rifaximina, proceso para preparación del mismo y composiciones de liberación controlada que contienen dicha rifaximina útiles para obtener un efecto de larga duración - Google Patents
Polvo de rifaximina, proceso para preparación del mismo y composiciones de liberación controlada que contienen dicha rifaximina útiles para obtener un efecto de larga duración Download PDFInfo
- Publication number
- ES2496771T3 ES2496771T3 ES11714663.9T ES11714663T ES2496771T3 ES 2496771 T3 ES2496771 T3 ES 2496771T3 ES 11714663 T ES11714663 T ES 11714663T ES 2496771 T3 ES2496771 T3 ES 2496771T3
- Authority
- ES
- Spain
- Prior art keywords
- rifaximin
- preparation
- powder
- controlled release
- obtaining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Un proceso para la preparación de polvo de rifaximina que tiene un espectro de difracción de rayos X correspondiente a una forma amorfa, que tiene un tamaño de partícula entre 40 y 120 micrómetros en un porcentaje de 90% de las partículas totales como se determina utilizando un analizador de tamaño de partícula Beckman- Coulter LS100 Q equipado con una celdilla de micro-volumen, y una densidad a granel entre 0,1 y 0,5 g/ml como se determina utilizando un matraz aforado de 10 ml, caracterizado por los pasos de: a) solubilización de rifaximina cristalina o amorfa, o sus mezclas, en disolventes orgánicos o sus mezclas; b) pulverización de dicha solución en un aparato de lecho fluido a una presión comprendida entre 0,5 y 2,5 bar en una corriente de aire templado; c) secado de la rifaximina sólida hasta peso constante a una temperatura comprendida entre 20ºC y 120ºC.
Description
E11714663
27-08-2014
TABLA 1
- Comparación de Valores PK perro-hombre que recibieron rifaximina -Valores medios ± error estándar
- Cmax (ng/ml)
- Tmax (h) AUC0-24h (ng.h/ml)
- Valores observados en perros después de administración de 100 mg/kg (Tabla 14) correspondiente a una HED de 54,4 mg/kg
- 1044,1 ± 588,46 2 2854,31 ± 1489,87
- Valores calculados en humanos reducidos proporcionalmente a la dosis de 2,9 mg/kg
- 56,1 ± 31,63 ND 143,4 ± 80,10
- Valores observados en humanos después de administración de tabletas de 200 mg correspondientes a 2,9 mg/kg
- 3,70 ± 0,55 1,04 11,47 ± 2,35
Por comparación de los valores de los parámetros PK calculados a 2,9 mg/kg HED obtenidos sobre la base del experimento en perros con los observados en humanos, cuando está comprendida en la preparación farmacéutica
5 del Ejemplo 3 la rifaximina del Ejemplo 1, se deduce que la nueva composición, por combinación del efecto de la forma de rifaximina y la composición farmacéutica, como se describe en el Ejemplo 3, reduce los niveles de biodisponibilidad de rifaximina en sangre si se compara con una administración directa de la rifaximina preparada por el método de secado por pulverización, como se describe en el Ejemplo 1.
La composición farmacéutica de las tabletas obtenidas conforme al Ejemplo 3 exhibe de hecho el resultado
10 inesperado derivado de la combinación de parámetros que actúan en direcciones opuestas: la rifaximina producida por el proceso de secado por pulverización conduce a rifaximina más soluble con un posible aumento de la biodisponibilidad, mientras que la composición y la forma farmacéutica en tabletas y el método de producción limitan el nivel de absorción, dando como resultado una liberación controlada.
La evidencia de la propiedad de la formulación se muestra en las Figuras 1 y 2, que consignan los valores de
15 concentraciones en plasma en dos individuos voluntarios diferentes, calculadas después de administraciones repetidas de formulaciones en tabletas que contienen la rifaximina preparada conforme al Ejemplo 3 si se compara con el producto comercial Normix®.
La comparación de los dos perfiles en los dos individuos voluntarios sanos tratados con la formulación de la presente invención demuestra que en ningún intervalo de tiempo a lo largo de la terapia total se exhibe cantidad
20 alguna de rifaximina detectable en el plasma, mientras que los pacientes tratados con las tabletas disponibles comercialmente que contenían rifaximina (Normix®) exhiben concentraciones en plasma de rifaximina no detectables analíticamente.
Por tanto, un aspecto de la invención es una composición capaz de liberar rifaximina en condiciones de liberación predecible y controlada. Dicha composición comprende un polvo de rifaximina que tiene la característica
25 morfológica arriba descrita, y que se obtiene por un proceso de secado por pulverización.
14
E11714663
27-08-2014
TABLA 2
- Parámetros del proceso
- Precalentamiento Pulverización Secado
- Volumen del aire de entrada
- 800 ± 200 m3/h 800 ± 200 m3/h 800 ± 200 m3/h
- Temperatura del aire de entrada
- 90 ± 10°C 90 ± 10°C 60 ± 5°C
- Presión de pulverización
- 0,7 ± 0,2 bar
- Tasa de pulverización
- 50 -380 g/min
- Temperatura del producto
- 55 -70°C 50 ± 2°C
El polvo de rifaximina obtenido se analiza por espectroscopia de rayos X, espectrometría 13C-NMR y espectroscopia IR, y es estable a una temperatura de 40ºC ± 2 con una humedad relativa de 75% hasta 3 meses.
5 El espectro de difracción de rayos X se consigna en la Figura 3, que muestra halo-picos que tienen máximos a 7,75º ± 1,02, 14,54º ± 0,2 y 18,33 ± 0,2, 2θ.
El espectro de difracción de rayos X se obtiene por la geometría Bragg-Brentano en las condiciones siguientes: tubo de rayos X: cobre; radiación: K(α1), K(α2); tensión de la corriente del generador: KV 40, mA 40; monocromador: grafito; tamaño de paso 0,02; tiempo de paso: 1,25 segundos; valor angular inicial y final de 2θ: 3,0º-30,0 ± 0,2d.
10 La Figura 4 muestra el espectro 13C-NMR obtenido por el instrumento Varian 400 a 100,56 MHz, por fusión de la muestra de cloroformo que tiene una pureza mayor que 99,8% y que contiene tetrametilsilano como patrón interno.
La Figura 5 muestra el espectro IR obtenido con el equipo Spectrum One, Perkin Elmer, utilizando una dispersión al 0,5% de rifaximina en bromuro de potasio, y registrándose el espectro a frecuencias de 4000 a 450 cm-1 .
La rifaximina así obtenida es estable, como se muestra en la Tabla 3.
15 TABLA 3
- Rifaximina obtenida por el Ejemplo 1 y mantenida a T = 40°C ± 2°C con humedad relativa = 75 ± 5%
- Test
- Criterios de aceptación T0 1 mes 3 meses
- Descripción
- Polvo amarillo anaranjado Polvo amarillo anaranjado Polvo amarillo anaranjado Polvo amarillo anaranjado
- Espectro FT-IT
- Cumple con con el estándar Cumple con con el estándar Cumple con con el estándar Cumple con con el estándar
- Espectro de difracción de rayos X
- Cumple con una forma amorfa de rifaximina Cumple con una forma amorfa de rifaximina Cumple con una forma amorfa de rifaximina Cumple con una forma amorfa de rifaximina
- Contenido de agua (Karl Fisher)
- ≤ 8% 2,2% 4,9% 5,4%
- Impurezas totales
- ≤ 2,0% 0,51% 0,54% 0,95%
16
E11714663
27-08-2014
La densidad de la rifaximina obtenida por secado por pulverización es 0,257 g/ml, y la densidad de la rifaximina obtenida por molienda es 0,327 g/ml.
e) Superficie Específica (BET)
Para la determinación de las áreas de superficie baja se utilizó una técnica de gas fluyente. Los análisis se
5 realizaron utilizando nitrógeno gaseoso sobre 300 mg de muestra secada a vacío, aumentado la temperatura desde 25ºC a 100ºC con una tasa de calentamiento de 10ºC/min. La superficie específica de la rifaximina obtenida por secado por pulverización está comprendida entre 0,01 y 5 m2/g, y la superficie específica de la rifaximina obtenida por molienda está comprendida entre 6 y 12 m2/g.
f) Solubilidad
10 500 mg de cada preparación de rifaximina consignada en el Ejemplo 1 y rifaximina obtenida por molienda, respectivamente, se suspendieron por separado en 750 ml de una solución tampón acuosa de fosfatos, pH 6,8, temperatura 30 ± 0,5ºC.
Las soluciones que contienen rifaximina suspendida se agitan por medio de un agitador de barrido durante 150 minutos a la tasa de agitación de 250 rpm. Las muestras tomadas a intervalos de 5 minutos durante la primera hora
15 y a intervalos de 15 minutos en el tiempo restante se analizan en HPLC después de filtración. Los resultados se consignan en la Tabla 5.
TABLA 5
- Solubilidad a lo largo del tiempo de la preparación de rifaximina
- Concentración (mg/l)
- Tiempo (min)
- Secado por Pulverización Molienda
- 5
- 14,4 10,8
- 10
- 30,2 14,3
- 15
- 44,0 15,9
- 20
- 47,0 16,7
- 25
- 38,0 16,9
- 30
- 28,7 16,7
- 35
- 22,4 16,1
- 40
- 17,7 15,4
- 4S
- 14,9 14,8
- 50
- 13,1 14,0
- 55
- 11,8 13,5
- 60
- 11,0 12,9
- 75
- 9,9 12,1
- 90
- 9,5 10,9
- 105
- 9,3 9,8
18
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2010A000370A IT1398550B1 (it) | 2010-03-05 | 2010-03-05 | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
ITMI20100370 | 2010-03-05 | ||
PCT/IB2011/050933 WO2011107970A2 (en) | 2010-03-05 | 2011-03-04 | Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect. |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2496771T3 true ES2496771T3 (es) | 2014-09-19 |
Family
ID=42697389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11714663.9T Active ES2496771T3 (es) | 2010-03-05 | 2011-03-04 | Polvo de rifaximina, proceso para preparación del mismo y composiciones de liberación controlada que contienen dicha rifaximina útiles para obtener un efecto de larga duración |
Country Status (28)
Country | Link |
---|---|
US (2) | US8748447B2 (es) |
EP (1) | EP2542225B1 (es) |
JP (1) | JP5932669B2 (es) |
KR (1) | KR101663491B1 (es) |
CN (1) | CN102781432B (es) |
AU (1) | AU2011222432B2 (es) |
BR (1) | BR112012021681A8 (es) |
CA (1) | CA2787123C (es) |
CL (1) | CL2012002124A1 (es) |
CO (1) | CO6551760A2 (es) |
DK (1) | DK2542225T3 (es) |
EA (1) | EA022324B1 (es) |
ES (1) | ES2496771T3 (es) |
HK (1) | HK1174263A1 (es) |
HR (1) | HRP20140876T1 (es) |
IL (1) | IL220792A (es) |
IT (1) | IT1398550B1 (es) |
MX (1) | MX2012010233A (es) |
NZ (1) | NZ602230A (es) |
PL (1) | PL2542225T3 (es) |
PT (1) | PT2542225E (es) |
RS (1) | RS53609B1 (es) |
SG (1) | SG182523A1 (es) |
SI (1) | SI2542225T1 (es) |
TN (1) | TN2012000362A1 (es) |
UA (1) | UA107208C2 (es) |
WO (1) | WO2011107970A2 (es) |
ZA (1) | ZA201205537B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1698630B1 (en) | 2005-03-03 | 2014-09-03 | ALFA WASSERMANN S.p.A. | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
EP2401282B2 (en) | 2009-12-28 | 2017-01-04 | Silvio Massimo Lavagna | Method for the production of amorphous rifaximin |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
CA2800235C (en) * | 2010-03-10 | 2018-10-16 | Lupin Limited | Rifaximin ready-to-use suspension |
ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
US9849090B2 (en) | 2012-12-12 | 2017-12-26 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of rifaximin |
WO2016019372A1 (en) * | 2014-08-01 | 2016-02-04 | Bioxcel Corporation | Methods for reformulating and repositioning pharmaceutical data and devices thereof |
WO2016063289A2 (en) * | 2014-10-22 | 2016-04-28 | Strides Arcolab Limited | Pharmaceutical tablet compositions comprising rifaximin |
CN107580493A (zh) * | 2015-05-08 | 2018-01-12 | 沃克哈特有限公司 | 包含抗细菌剂的稳定的药物组合物 |
ES2738024T5 (es) | 2016-03-24 | 2022-10-24 | Sandoz Ag | Composición estable al almacenamiento que comprende rifaximina alfa |
US10576065B2 (en) | 2016-03-24 | 2020-03-03 | Sandoz Ag | Pharmaceutical composition containing rifaximin alpha and delta |
PL3518924T3 (pl) | 2016-09-30 | 2023-01-09 | Salix Pharmaceuticals, Inc. | Postacie stałej dyspersji ryfaksyminy |
WO2020208140A1 (en) * | 2019-04-12 | 2020-10-15 | Sandoz Ag | Rifaximin-containing granules |
WO2023067485A1 (en) * | 2021-10-19 | 2023-04-27 | Zydus Lifesciences Limited | Pharmaceutical combinations |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
DE3113139A1 (de) | 1981-04-01 | 1982-10-21 | Smit Transformatoren B.V., 6500 Nijmegen | "trockentransformator oder drosselspule mit luftkuehlung" |
IT1199374B (it) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
US5356625A (en) | 1986-08-28 | 1994-10-18 | Enzacor Properties Limited | Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals |
GB8816620D0 (en) | 1988-07-13 | 1988-08-17 | Lepetit Spa | Rifapentine hydrohalides |
JP3350861B2 (ja) | 1990-06-29 | 2002-11-25 | アベンテイス・バルク・ソチエタ・ペル・アチオニ | リファペンチンの純粋の結晶型 |
IT1253711B (it) | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali |
IT1264494B1 (it) | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
WO1998016111A1 (en) | 1996-10-16 | 1998-04-23 | Shaman Pharmaceuticals, Inc. | Enteric formulations of proanthocyanidin polymer antidiarrheal compositions |
IT1290679B1 (it) | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
US20030157174A1 (en) | 2000-03-23 | 2003-08-21 | Takayuki Tsukuda | Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component |
US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
US6906087B2 (en) | 2000-10-31 | 2005-06-14 | Ciba Specialty Chemicals Corpation | Crystalline forms of venlafaxine hydrochloride |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
US20080262024A1 (en) | 2003-11-07 | 2008-10-23 | Giuseppe Claudio Viscomi | Rifaximin compositions and method of use |
US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
US7923553B2 (en) | 2003-11-07 | 2011-04-12 | Alfa Wassermann, S.P.A. | Processes for the production of polymorphic forms of rifaximin |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
US20050196418A1 (en) | 2004-03-04 | 2005-09-08 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
EP1698630B1 (en) | 2005-03-03 | 2014-09-03 | ALFA WASSERMANN S.p.A. | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
EP2069363B1 (en) * | 2006-09-22 | 2013-03-20 | Cipla Ltd. | Rifaximin in an amorphous form |
ITMI20071241A1 (it) | 2007-06-20 | 2008-12-21 | Solmag S P A | Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta |
US8974825B2 (en) | 2007-07-06 | 2015-03-10 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
WO2009008005A1 (en) | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions of rifaximin |
EP2837378A1 (en) | 2007-07-06 | 2015-02-18 | Lupin Limited | Pharmaceutical compositions of rifaximin |
US7709634B2 (en) * | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
SG188931A1 (en) | 2008-02-25 | 2013-04-30 | Salix Pharmaceuticals Ltd | Forms of rifaximin and uses thereof |
US8486956B2 (en) | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
WO2010044093A1 (en) | 2008-10-16 | 2010-04-22 | Strides Arcolab Limited | Formulations containing rifaximin |
AU2009326167A1 (en) | 2008-12-10 | 2010-06-17 | Cipla Limited | Rifaximin complexes |
IT1397617B1 (it) | 2009-04-20 | 2013-01-18 | Alfa Wassermann Spa | Nuovi derivati della rifamicina |
ES2762442T3 (es) | 2009-10-26 | 2020-05-25 | Borody Thomas J | Novedosa terapia de combinación entérica |
EP2493456B1 (en) | 2009-10-27 | 2018-11-21 | Lupin Limited | Solid dispersion of rifaximin |
WO2011061748A1 (en) | 2009-11-19 | 2011-05-26 | Strides Arcolab Limited | Rifaximin premix |
RU2012126080A (ru) | 2009-11-23 | 2013-12-27 | Сипла Лимитед | Местная пенообразующая композиция |
JP2013511570A (ja) | 2009-11-23 | 2013-04-04 | シプラ・リミテッド | 局所用泡沫組成物 |
EP2401282B2 (en) | 2009-12-28 | 2017-01-04 | Silvio Massimo Lavagna | Method for the production of amorphous rifaximin |
CN101773465B (zh) | 2010-01-19 | 2012-11-07 | 南京泛太化工医药研究所 | 以氨基酸为稳定剂的聚合物胶束载药系统 |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
CA2800235C (en) | 2010-03-10 | 2018-10-16 | Lupin Limited | Rifaximin ready-to-use suspension |
CN103269587A (zh) | 2010-06-03 | 2013-08-28 | 萨利克斯药品有限公司 | 利福昔明的新形式及其用途 |
US8883795B2 (en) | 2010-06-16 | 2014-11-11 | Apotex Pharmachem Inc. | Polymorphic forms of Rifaximin |
CN103228662B (zh) | 2010-07-12 | 2016-08-10 | 萨利克斯药品有限公司 | 利福昔明的制剂及其用途 |
US8759513B2 (en) | 2010-09-13 | 2014-06-24 | Sequent Scientific Limited | Polymorphic form of rifaximin and process for its preparation |
US20130315988A1 (en) | 2010-09-13 | 2013-11-28 | Cipla Limited | Pharmaceutical Composition |
IT1403847B1 (it) | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
WO2012076832A1 (en) | 2010-12-09 | 2012-06-14 | Cipla Limited | Suppositories comprising rifaximin |
PL2672970T3 (pl) | 2011-02-11 | 2018-11-30 | Salix Pharmaceuticals, Ltd. | Postacie rifaksyminy i sposoby ich wykorzystania |
AU2012251385A1 (en) | 2011-05-02 | 2013-11-21 | Ranbaxy Laboratories Limited | Rifaximin dimethylformamide solvate |
ITMI20110890A1 (it) | 2011-05-19 | 2012-11-20 | A M S A Anonima Materie Sint & Affini S P A | Polimorfo di rifaximina e processo per la sua preparazione |
ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
US9359374B2 (en) | 2012-06-13 | 2016-06-07 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
US9849090B2 (en) | 2012-12-12 | 2017-12-26 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of rifaximin |
ITMI20131307A1 (it) | 2013-08-02 | 2015-02-02 | A M S A Anonima Materie Sint & Affini S P A | Processo per la preparazione di refaximina k |
-
2010
- 2010-03-05 IT ITMI2010A000370A patent/IT1398550B1/it active
-
2011
- 2011-03-04 AU AU2011222432A patent/AU2011222432B2/en active Active
- 2011-03-04 SG SG2012051975A patent/SG182523A1/en unknown
- 2011-03-04 BR BR112012021681A patent/BR112012021681A8/pt not_active Application Discontinuation
- 2011-03-04 SI SI201130298T patent/SI2542225T1/sl unknown
- 2011-03-04 WO PCT/IB2011/050933 patent/WO2011107970A2/en active Application Filing
- 2011-03-04 EA EA201290734A patent/EA022324B1/ru unknown
- 2011-03-04 NZ NZ602230A patent/NZ602230A/xx unknown
- 2011-03-04 JP JP2012555537A patent/JP5932669B2/ja not_active Expired - Fee Related
- 2011-03-04 PT PT117146639T patent/PT2542225E/pt unknown
- 2011-03-04 RS RS20140619A patent/RS53609B1/en unknown
- 2011-03-04 EP EP11714663.9A patent/EP2542225B1/en active Active
- 2011-03-04 CN CN201180012550.XA patent/CN102781432B/zh active Active
- 2011-03-04 US US13/582,676 patent/US8748447B2/en active Active
- 2011-03-04 DK DK11714663.9T patent/DK2542225T3/da active
- 2011-03-04 KR KR1020127022961A patent/KR101663491B1/ko active IP Right Grant
- 2011-03-04 MX MX2012010233A patent/MX2012010233A/es unknown
- 2011-03-04 PL PL11714663T patent/PL2542225T3/pl unknown
- 2011-03-04 ES ES11714663.9T patent/ES2496771T3/es active Active
- 2011-03-04 CA CA2787123A patent/CA2787123C/en active Active
- 2011-04-03 UA UAA201208484A patent/UA107208C2/uk unknown
-
2012
- 2012-07-05 IL IL220792A patent/IL220792A/en active IP Right Grant
- 2012-07-17 TN TNP2012000362A patent/TN2012000362A1/en unknown
- 2012-07-23 ZA ZA2012/05537A patent/ZA201205537B/en unknown
- 2012-07-30 CO CO12127400A patent/CO6551760A2/es not_active Application Discontinuation
- 2012-07-31 CL CL2012002124A patent/CL2012002124A1/es unknown
-
2013
- 2013-01-31 HK HK13101372.1A patent/HK1174263A1/xx unknown
-
2014
- 2014-04-24 US US14/261,337 patent/US9498442B2/en active Active
- 2014-09-15 HR HRP20140876AT patent/HRP20140876T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2496771T3 (es) | Polvo de rifaximina, proceso para preparación del mismo y composiciones de liberación controlada que contienen dicha rifaximina útiles para obtener un efecto de larga duración | |
JP6946194B2 (ja) | キナーゼを調節する化合物の固体形態 | |
CN105530916B (zh) | 与间水杨酸形成的烟碱盐 | |
CN100496458C (zh) | 用于吸入递送的气溶胶的形成方法 | |
ES2704688T3 (es) | Uso de estearato de magnesio en formulaciones de polvo seco para inhalación | |
ES2650791T3 (es) | Estabilización de composiciones farmacéuticas | |
ES2634943T3 (es) | Formulación de polvo seco de derivado de azol para inhalación | |
ES2527622T3 (es) | Formulación de galio para el tratamiento y la prevención de enfermedades infecciosas | |
BR112020011625A2 (pt) | formas sólidas de canabidiol e usos das mesmas | |
ES2899367T3 (es) | Forma amorfa de trifenatato de vilanterol y procedimientos para su preparación | |
Wang et al. | Dexamethasone sodium phosphate intercalated layered double hydroxides and their therapeutic efficacy in a murine asthma model | |
Luz et al. | Designing inhalable metal organic frameworks for pulmonary tuberculosis treatment and theragnostics via spray drying | |
US20230398112A1 (en) | Spray-dried metal-organic frameworks for treatment and/or diagnosis of pulmonary disease | |
Wang et al. | Solid-state characterization of 17β-estradiol co-crystals presenting improved dissolution and bioavailability | |
Sun et al. | Allyl isothiocyanate dry powder inhaler based on cyclodextrin-metal organic frameworks for pulmonary delivery | |
CA2888431A1 (en) | Pharmaceutical formulation comprising ciclesonide | |
ES2587064T3 (es) | Sales fumarato novedosas de un antagonista del receptor de histamina H3 | |
ES2361908T3 (es) | Un dispositivo formador de aerosol para uso en terapia de inhalación. | |
Agrawal et al. | Solubility enhancementofcefixime trihydrate by solid dispersions using hydrotropic solubilization technique and their characterization | |
Kumar et al. | Biomimicked and CPMV-Imprinted Hollow Porous Zinc Phosphate Nanocapsules and Their Therapeutic Efficiency | |
JP7285615B2 (ja) | 不純物の生成を抑制した医薬組成物 | |
BR112021008732A2 (pt) | ingredientes farmacêuticos amorfos ativos compreendendo carbonato de magnésio mesoporoso substancialmente amorfo | |
Ijbara et al. | Release kinetics of nicotine loaded onto mesoporous silicate materials for use in nicotine replacement therapy | |
ES2927460T3 (es) | Citrato de vareniclina en micropartículas | |
Sruti et al. | Cefuroxime Axetil dissolution improvement by preparation of solid dispersions with porous carrier |